Corporate Banner
Satellite Banner
RNAi
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Dako to Offer New Antibody in U.S. to Diagnose Breast Cancer

Published: Monday, April 08, 2013
Last Updated: Monday, April 08, 2013
Bookmark and Share
Dako receives clearance to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor a, Clone EP1 in US.

Dako has recently received clearance from the U.S. Food and Drug Administration to sell FLEX Monoclonal Rabbit Anti-Human Estrogen Receptor α, Clone EP1 in the United States.

The clone has been available in Europe for some time and has enjoyed widespread acceptance.

“We are very pleased to now be able to supply our customers in the United States with this high-quality antibody for estrogen receptor testing on Dako’s Autostainer Link 48,” said Karen Balstrup, global product manager, IHC Reagents, at Dako.

Research has shown that tumor growth is dependent on the presence of estrogen, progesterone or both in most breast cancers.

Estrogen receptor (ER) status in breast carcinomas is a validated prognostic and predictive factor for managing a patient’s anti-hormonal therapy.

With this important diagnostic tool from Dako, breast cancer patients can be confident they are receiving the most effective treatment for their particular type of breast cancer.

Clone EP1 shows excellent concordance with the existing ER component from Dako’s ER/PR pharmDx Kit, with an overall agreement of 97.7 percent, a strong indication that pathologists can rely on the results obtained from using this antibody.

“Clone EP1 specifically detects nuclear estrogen receptor without cytoplasmic staining and shows a high degree of concordance (greater than 95 percent) to existing clones,” said Sunil S. Badve, M.D., Department of Pathology and Laboratory Medicine, Indiana University.

Badve continued, “Compared with other established ER antibody assays this new clone is a highly sensitive and specific antibody.”

The Monoclonal Rabbit Anti-Human ER α, Clone EP1 was created by Epitomics Inc., using Epitomics’ proprietary rabbit monoclonal antibody technology covered under Patent Nos. 5,675,063 and 7,402,409.

Dako and Epitomics entered into a collaboration in 2011 which allows the companies to unite competencies to provide the anatomic pathology market with antibodies.


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,000+ scientific posters on ePosters
  • More than 4,500+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Best Practices for Breast Cancer Diagnosis
Agilent has published “Breast Cancer Diagnosis: Past, Present and Future,” a white paper on the use of immunohistochemistry in diagnosing and treating breast cancer.
Monday, March 14, 2016
Dako, Cell Signalling Tech Partner with Companion Diagnostics
Partnership for development of high-quality, cutting-edge companion diagnostic products for diagnosis and treatment of cancer.
Monday, January 12, 2015
Agilent, Cell Line Genetics Collaborate
Companies to collaborate on high-throughput cell-line characterization services for regenerative medicine, cancer researchers.
Thursday, February 13, 2014
Dr. Emmanuel Barillot Receives Agilent Thought Leader Award
Award will support Dr. Barillot’s Web-based tools for cancer and drug-safety research.
Friday, August 30, 2013
Agilent Technologies Thought Leader Award Supports Translational Research Program
The award will support Dr DePinho's research into metabolic reprogramming in the earliest stages of cancer.
Monday, March 04, 2013
Agilent Technologies Teams with University of Liverpool's Centre for Genomic Research
Centre for Genomic Research has become the UK's first Certified Service Provider for the Agilent SureSelect Target Enrichment System for next-generation sequencing.
Wednesday, August 08, 2012
Agilent Technologies Collaborates with Gachon University
World-leading research laboratory at Gachon will have access to the latest technologies from Agilent and a beta test site for new solutions.
Monday, July 23, 2012
Agilent Completes Acquisition of Dako, Danish Cancer Diagnostics Company
Acquisition to help strengthen Agilent's position in life sciences.
Thursday, June 28, 2012
Agilent to Acquire Dako for $2.2 Billion
The largest acquisition in Agilent’s history is the next step in their growing role in clinical diagnostics.
Friday, May 18, 2012
Agilent Appoints Molecular Genomics as its First Certified Service Provider for Microarrays in Singapore
Molecular Genomics offers microarray services using the Agilent CGH/SNP microarrays, gene expression, and microRNA products.
Monday, July 25, 2011
Agilent Appoints BGI First Certified Service Provider in China for Target Enrichment System for Next-Gen Sequencing
Certified for all SureSelect XT target enrichment protocols including human all-exon, SureSelect indexing, DNA capture, RNA capture, kinome RNA and custom kits.
Sunday, April 17, 2011
Agilent Technologies Acquire Lab901
Agilent Technologies Inc. announces that it has acquired the Edinburgh-based electrophoresis equipment and consumables company, Lab901.
Thursday, March 03, 2011
Agilent Debuts RNA Target Enrichment, Streamlining Transcriptome Profiling Studies to Advance Cancer and Stem Cell Research
Company has introduced SureSelect RNA Capture Kits, enabling geneticists to focus on specific genomic loci or transcripts of research interest.
Wednesday, February 09, 2011
Agilent Technologies Extends Million-Feature Format to Gene Expression Microarrays
Agilent SurePrint G3 Gene Expression Microarrays provides up to one million features per standard 1-by-3-inch slide for added throughput.
Tuesday, May 18, 2010
Automating Viral RNA Genotyping
Agilent Automation Solutions has released a new applications bulletin that describes an automated system for rapid characterization of pathogens, including for example the Influenza A (H1N1) virus.
Thursday, February 18, 2010
Scientific News
Turning Skin Cells into Heart, Brain Cells
In a major breakthrough, scientists at the Gladstone Institutes transformed skin cells into heart cells and brain cells using a combination of chemicals.
Detection of HPV in First-Void Urine
Similar sensitivity of HPV test on first void urine sample compared to cervical smear.
Potential “Good Fat” Biomarker
New method to measure the activity of energy consuming brown fat cells could ease the testing weight loss drugs.
Shape Of Tumor May Affect Whether Cells Can Metastasize
Illinois researchers found that the shape of a tumor may play a role in how cancer cells become primed to spread.
MicroRNA Pathway Could Lead to New Avenues for Leukemia Treatment
Cancer researchers at the University of Cincinnati have found a particular signaling route in microRNA (miR-22) that could lead to targets for acute myeloid leukemia, the most common type of fast-growing cancer of the blood and bone marrow.
Analysis of Dog Genome will Provide Insight into Human Disease
An important model in studying human disease, the non-coding RNA of the canine genome is an essential starting point for evolutionary and biomedical studies – according to a new study led by The Genome Analysis Centre (TGAC).
New Blood Test for The Earlier Diagnosis of Breast Cancer Spread
Researchers at University of Westminster have confirmed that a new blood test can detect if breast cancer has spread to other parts of the body.
First Gene Therapy Successful Against Human Aging
American woman gets biologically younger after gene therapies.
Targeting an ‘Undruggable’ Cancer Gene
RAS genes are mutated in more than 30 percent of human cancers and represent one of the most sought-after cancer targets for drug developers.
Altered Metabolism of Four Compounds Drives Glioblastoma Growth
Findings suggest new ways to treat the malignancy, slow its progression and reveal its extent more precisely.
SELECTBIO

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,000+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
4,500+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!